VertexPharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
VertexPharmaceuticals achieved compound earnings per share (EPS) growth of 1.5% per year. We do note that extraordinary items have impacted its earnings history. This EPS growth is lower than ...